Investors should expect 96-week data in October.
NDA is still expected for H1 2014.
FDA will look at the totality of the data and could grant full approval (versus accelerated approval) based on robust clinical outcomes.
Manufacturing scale up is proceeding — the company should be ready for commercial launch by the end of 2014. (webcast)